Alex Rinehart, PhD, identifies the target population for cabotegravir.
Alex Rinehart, PhD, Director, Global Prevention Strategy, ViiV Healthcare, explains who the target population is for cabotegravir. Dr. Rinehart stresses that essentially, anyone who is at risk for HIV can use cabotegravir as a preventive option against the virus.
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.